Dianes farmacològiques en inflamació i malalaties metabòliques

Resistència a la insulina i inflamació. NAFLD. NASH. Cardiomiopatia diabètica. Noves dianes farmacològiques en resistència a la insulina-diabetis mellitus tipus 2.

Cultiu cel·lular (adipòcit, hepatòcit, miòcit i cardiomiòcit), RT-PCR, Western-blot, co-immunoprecipitació, EMSA, models animals (obesitat, diabetes tipus 1 i 2, NAFLD, NASH, pancreatitis).

1. Títol: Nous activadors de l’HRI pel tractament de l’esteatohepatitis no alcohòlica. Codi: F2I-FVal_2019-018. IP: Manuel Vázquez Carrera. Data: 15/12/2019-15/12/2020. Import: 25.000,00 €. Entitat: Fundació Bosch i Gimpera de la Universitat de Barcelona.

2. Títol: Estudi de nous fàrmacs contra l'esteatosi hepàtica. IP: Manuel Vázquez Carrera/Emma Barroso. Data: 01/12/2018-01/05/2019. Import: 8.223,00 €. Entitat: Laboratorios Almirall, S.A.

3. Títol: ACTIVACION DE PPARB/D Y HRI: EXPLORANDO NUEVOS MECANISMOS COMPENSATORIOS PARA EL TRATAMIENTO DE LA INFLAMACION, LA RESISTENCIA A LA INSULINA Y LA ESTEATOHEPATITIS NO ALCOHOLICA. Codi: RTI2018-093999-B-I00. IP: Manuel Vázquez Carrera/Xavier Palomer. Data: 01/09/2019- 31/12/2021. Import: 240.000,00 €. Entitat: MINECO.

4. Títol: Effect of VBT-0011 on PPAR mice energetic metabolism.  IP: Manuel Vázquez Carrera Data: 22/11/2018-07/03/2019. Import: 21.000,00 €. Entitat: Laboratoris Valbiotis.

5. Títol: Activadors de la HRI pel tractament de la diabetis mellitus tipus 2 i altres patologies associades. IP: Manuel Vázquez Carrera. Data: 07/01/2017-07/01/2018. Import: 25.000,00 €. Entitat: Fundació Bosch i Gimpera de la Universitat de Barcelona.

6. Títol: New HRI activators for the treatment of type 2 Diabetes Mellitus. IP: Manuel Vázquez Carrera. Data: 01/01/2019-31/12/2020. Import: 100.000,00 €. Entitat: CaixaImpulse.

7. Títol: INFLAMACION, RESISTENCIA A LA INSULINA Y CARDIOMIOPATIA DIABETICA: EVALUACION DE LOS AGONISTAS PPARBETA/DELTA Y DEL ACIDO OLEICO.  Codi: SAF2015-64146-R. IP: Manuel Vázquez Carrera. Data: 01/01/2016- 31/12/2018. Import: 229.900,00 €. Entitat: MINECO.

1. Palomer X, Román-Azcona MS, Pizarro-Delgado J, Planavila A, Villarroya F, Valenzuela-Alcaraz B, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E, Vázquez-Carrera M.  SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation. Signal Transduct Target Ther. 2020 Feb 28;5:14.

2. Zarei M, Pizarro-Delgado J, Barroso E, Palomer X, Vázquez-Carrera M.  Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends Pharmacol Sci. 2020 Mar;41(3):199-208.

3. Puigoriol-Illamola D, Leiva R, Vázquez-Carrera M, Vázquez S, Griñán-Ferré C, Pallàs M. 11β-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress. Mol Neurobiol. 2020 Jan;57(1):551-565.

4. Zarei M, Pujol E, Quesada-López T, Villarroya F, Barroso E, Vázquez S, Pizarro-Delgado J, Palomer X, Vázquez-Carrera M. Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. Br J Pharmacol. 2019 Jul;176(13):2292-2305.

5. Márquez A, Aymerich J, Dei M, Rodríguez-Rodríguez R, Vázquez-Carrera M, Pizarro-Delgado J, Giménez-Gómez P, Merlos Á, Terés L, Serra-Graells F, Jiménez-Jorquera C, Domínguez C, Muñoz-Berbel X. Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients. Biosens Bioelectron. 2019 Jul 1;136:38-46.

6. Rodríguez-Calvo R, Girona J, Rodríguez M, Samino S, Barroso E, de Gonzalo-Calvo D, Guaita-Esteruelas S, Heras M, van der Meer RW, Lamb HJ, Yanes O, Correig X, Llorente-Cortés V, Vázquez-Carrera M, Masana L. Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes. Metabolism. 2019 Jul;96:12-21.

7. Busquets O, Eritja À, López BM, Ettcheto M, Manzine PR, Castro-Torres RD, Verdaguer E, Olloquequi J, Vázquez-Carrera M, Auladell C, Folch J, Camins A. Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model. J Neurochem. 2019 Apr;149(2):255-268.

8. Manzanares A, Restrepo-Perdomo CA, Botteri G, Castillo-Ecija H, Pascual-Pasto G, Cano F, Garcia-Alvarez L, Monterrubio C, Ruiz B, Vazquez-Carrera M, Suñol M, Mora J, Tornero JA, Sosnik A, Carcaboso AM. Tissue Compatibility of SN-38-Loaded Anticancer Nanofiber Matrices. Adv Healthc Mater. 2018 Aug;7(15):e1800255.

9. Palomer X, Pizarro-Delgado J, Vázquez-Carrera M. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets? Trends Pharmacol Sci. 2018 May;39(5):452-467.

10. Palomer X, Barroso E, Pizarro-Delgado J, Peña L, Botteri G, Zarei M, Aguilar D, Montori-Grau M, Vázquez-Carrera M. PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders. Int J Mol Sci. 2018 Mar 20;19(3):913.

11. Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer X, Vázquez-Carrera M. The BACE1 product sAPPβ induces ER stress and inflammation and impairs insulin signaling. Metabolism. 2018 Aug;85:59-75.

12. Montori-Grau M, Pedreira-Casahuga R, Boyer-Díaz Z, Lassot I, García-Martínez C, Orozco A, Cebrià J, Osorio-Conles O, Chacón MR, Vendrell J, Vázquez-Carrera M, Desagher S, Jiménez-Chillarón JC, Gómez-Foix AM. GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle. Metabolism. 2018 Jun;83:177-187.

13. Ettcheto M, Sánchez-López E, Gómez-Mínguez Y, Cabrera H, Busquets O, Beas-Zarate C, García ML, Carro E, Casadesus G, Auladell C, Vázquez Carrera M, Folch J, Camins A. Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. Mol Neurobiol. 2018 Sep;55(9):7327-7339.

14. Palomer X, Pizarro-Delgado J, Barroso E, Vázquez-Carrera M. Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends Endocrinol Metab. 2018 Mar;29(3):178-190.

15. Zarei M, Barroso E, Palomer X, Dai J, Rada P, Quesada-López T, Escolà-Gil JC, Cedó L, Zali MR, Molaei M, Dabiri R, Vázquez S, Pujol E, Valverde ÁM, Villarroya F, Liu Y, Wahli W, Vázquez-Carrera M. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. Mol Metab. 2018 Feb;8:117-131.

16. Botteri G, Montori M, Gumà A, Pizarro J, Cedó L, Escolà-Gil JC, Li D, Barroso E, Palomer X, Kohan AB, Vázquez-Carrera M. VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells. Diabetologia. 2017 Nov;60(11):2262-2273.

17. Rodríguez-Calvo R, Chanda D, Oligschlaeger Y, Miglianico M, Coumans WA, Barroso E, Tajes M, Luiken JJ, Glatz JF, Vázquez-Carrera M, Neumann D. Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):541-551.

18. Tan NS, Vázquez-Carrera M, Montagner A, Sng MK, Guillou H, Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ. Prog Lipid Res. 2016 Oct;64:98-122.

19. Zarei M, Barroso E, Leiva R, Barniol-Xicota M, Pujol E, Escolano C, Vázquez S, Palomer X, Pardo V, González-Rodríguez Á, Valverde ÁM, Quesada-López T, Villarroya F, Wahli W, Vázquez-Carrera M. Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency. Diabetes. 2016 Oct;65(10):3185-99.

20. Vázquez-Carrera M. Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. Trends Endocrinol Metab. 2016 May;27(5):319-334.